$15.23
6.58% today
NYSE, Feb 05, 04:23 pm CET
ISIN
US37611X1000
Symbol
DNA

Ginkgo Bioworks Stock price

$14.29
+2.64 22.66% 1M
+2.14 17.59% 6M
+4.47 45.52% YTD
-34.51 70.72% 1Y
-227.31 94.09% 3Y
-390.51 96.47% 5Y
-390.51 96.47% 10Y
NYSE, Closing price Tue, Feb 04 2025
+1.44 11.21%
ISIN
US37611X1000
Symbol
DNA
Sector

Key metrics

Market capitalization $778.50m
Enterprise Value $605.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.78
P/S ratio (TTM) P/S ratio 3.57
P/B ratio (TTM) P/B ratio 0.90
Revenue growth (TTM) Revenue growth -30.81%
Revenue (TTM) Revenue $217.95m
EBIT (operating result TTM) EBIT $-515.36m
Free Cash Flow (TTM) Free Cash Flow $-387.26m
Cash position $619.07m
EPS (TTM) EPS $-12.90
P/E forward negative
P/S forward 3.42
EV/Sales forward 2.66
Short interest 23.51%
Show more

Is Ginkgo Bioworks a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Ginkgo Bioworks Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

1x Buy
17%
1x Hold
17%
4x Sell
67%

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

Buy
17%
Hold
17%
Sell
67%

Financial data from Ginkgo Bioworks

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
218 218
31% 31%
100%
- Direct Costs 98 98
43% 43%
45%
120 120
16% 16%
55%
- Selling and Administrative Expenses 167 167
34% 34%
77%
- Research and Development Expense 408 408
31% 31%
187%
-455 -455
35% 35%
-209%
- Depreciation and Amortization 60 60
48% 48%
28%
EBIT (Operating Income) EBIT -515 -515
37% 37%
-236%
Net Profit -651 -651
24% 24%
-299%

In millions USD.

Don't miss a Thing! We will send you all news about Ginkgo Bioworks directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ginkgo Bioworks Stock News

Neutral
PRNewsWire
13 days ago
Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC BOSTON , Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled labor...
Neutral
Business Wire
15 days ago
LEXINGTON, Mass. & FREMONT, Calif.--(BUSINESS WIRE)--SaponiQx, a leader in saponin-based adjuvant discovery, is pleased to announce a strategic collaboration with Probius, a pioneer in quantum molecular spectroscopy for AI-driven discovery, and Ginkgo Bioworks. This partnership, fully funded by the Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemi...
Neutral
PRNewsWire
23 days ago
Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON , Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company...
More Ginkgo Bioworks News

Company Profile

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jason Kelly
Employees 1,218
Founded 2008
Website www.ginkgobioworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today